Research progress in tumor infiltrating lymphocyte therapy
10.3760/cma.j.cn112309-20240522-00175
- VernacularTitle:肿瘤浸润淋巴细胞疗法最新研究进展
- Author:
Hourui TAN
1
;
Ruiqi LIU
;
Peng DONG
;
Jianmin ZHANG
;
Wei HE
;
Hui CHEN
Author Information
1. 中国医学科学院北京协和医院肿瘤内科，北京 100005
- Keywords:
Tumor-infiltrating lymphocyte;
Solid tumor;
Immunotherapy
- From:
Chinese Journal of Microbiology and Immunology
2024;44(9):741-751
- CountryChina
- Language:Chinese
-
Abstract:
Tumor-infiltrating lymphocytes (TILs), derived from the solid tumor microenvironment, have significant advantages in adoptive cell therapy for solid tumors as they are believed to have more specific antitumor activity than peripheral lymphocytes. TILs was first reported in 1986. With the development and improvement of isolation and activation techniques, TILs-based adoptive cell therapy has shown long-term clinical benefit in phase Ⅱ/Ⅲ trials for advanced melanoma in recent years, and the first TILs-based therapy has been approved for market. Gene editing technology has improved the antitumor activity of TILs and made TILs widely used in other solid tumors besides advanced melanoma, such as head and neck cancer, breast cancer, non-small cell lung cancer, and ovarian cancer. In addition, TILs-based adoptive cell therapy used in combination with other tumor therapies has shown promising therapeutic potential in a variety of solid tumors. This review summarizes the significant progress of TILs-based therapy in basic research, clinical trials, and industrial application in the past two years, and analyzes the challenges and development trends, hoping to provide reference for further development in this field.
